Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
3 Dimensions for Diabetes (3DFD)
Khalida Ismail & Carol Gayle8th March 2016
King’s Fund, London
http://hww-kingsweb/news/display.asp?itemID=25532http://hww-kingsweb/news/display.asp?itemID=25532http://www.guysandstthomas.nhs.uk/Home.aspxhttp://www.guysandstthomas.nhs.uk/Home.aspx
Rochelle.....
• female, late 20s, single parent
• son age 4 years & daughter age 18 months
• type 1 diabetes in second pregnancy
• HbA1c 108 mmol/mol• Undetected severe post
partum depression
Depression and mortality in people with their first diabetic foot ulcer (n=253)
Ismail K, Winkley K, Stahl D, Chalder T, Edmonds M. Diabetes Care 2007:30;1473-9Winkley K, Sallis H, Kariyawasam D, Leelarathra L, Chalder T, Edmonds M, Stahl D, Ismail K. Diabetologia 2012;155:303-10
Funding: Wellcome Trust
Diabetes is associated with nearly every psychiatric disorder
ICD-10 Chapter F categories Relative risk
General popn/no psych disorder reference group
Dementia 2.0
Schizophrenia 3.0
Substance use ~?
Depression 2.0
Eating disorders 2-3.0
Chien et al Compr Psychiatry 2011; Anderson et al Diabetes Care 2000
Social problems
3DFD: a blank canvas
Parallel versus integrated services
Diabetes
Social
Mental Health
Diabetes
Social Mental Health
Active ingredients of 3DFD
•diagnostic assessment•risk management•psychotropic •brief psychological
treatments•family work
• patient-led MDT meeting• increase self efficacy for
diabetes • HbA1c• Patient reported outcomes
• medication support• biomedical monitoring• diabetes education• technology• complications
• debt management• housing support• occupational rehab• literacy• advocacy
Social interventions
Diabetes Management
Liaison mental health
services
Patient
3 Dimensions For Diabetes (3DFD) 1,2,3
Social Interventions
Diabetes management
Liaison mental health
services
Patient
Primary care Specialist care
1 BMJ Best Diabetes Team Award 20142 Doherty et al International Journal of Psychiatry in Medicine 20163 NHS Regional Innovation Fund London 2010
Challenges and Opportunities • Defining the model? Whatever it was-it had to be simple• Full integration into diabetes teams, community and hospitals• MDT, Education and training
De novo service
• ‘luxury service’• Pathways – Improving Access to Psychological Services (IAPT)• Commissioners
Organisational resistance
• Cross sector steering group with Diabetes Modernisation Initiative
• Evaluation, business case, dissemination & awards • Hospital charities and CCG funding• Commissioned service but needs scaling up
Sustainability
3DFD characteristicsYear 1
Oct 2012-2013
n=306
Year 2
Oct 2013-2014
n=255
Total
Oct 2012-2014
n=561
Age, mean (SD) 47 (14.8) 50 (15.1) 48 (14.9)
Gender n, (%) Male 121(39.4) 110 (43.3) 231 (41.2)
Female 181 (60.6) 144 (56.7) 325 (58.8)
Diagnosis n, (%) Type 1 89 (28.9) 60 (23.6) 149 (26.6)
Type 2 218 (71.1) 194 (76.4) 412 (73.4)
Ethnic group n, (%)
Caucasian 76 (24.7) 81 (31.9) 157 (28.0)
African/Caribbean 98 (31.9) 88 (34.6) 186 (33.2)
Other 133 (43.2) 88 (33.5) 218 (38.8)
HbA1cmean (SD)
% (DCCT) 10.7 (1.9) 11.6 (2.1) 11.1 (2.0)
mmol/mol (IFCC) 93 (10) 103 (11) 98 (10)
3DFD characteristicsYear 1
Oct 2012-2013
n=306
Year 2
Oct 2013-2014
n=255
Total
Oct 2012-2014
n=561
Age, mean (SD) 47 (14.8) 50 (15.1) 48 (14.9)
Gender n, (%) Male 121(39.4) 110 (43.3) 231 (41.2)
Female 181 (60.6) 144 (56.7) 325 (58.8)
Diagnosis n, (%) Type 1 89 (28.9) 60 (23.6) 149 (26.6)
Type 2 218 (71.1) 194 (76.4) 412 (73.4)
Ethnic group n, (%)
Caucasian 76 (24.7) 81 (31.9) 157 (28.0)
African/Caribbean 98 (31.9) 88 (34.6) 186 (33.2)
Other 133 (43.2) 88 (33.5) 218 (38.8)
HbA1cmean (SD)
% (DCCT) 10.7 (1.9) 11.6 (2.1) 11.1 (2.0)
mmol/mol (IFCC) 93 (10) 103 (11) 98 (10)
3DFD characteristicsYear 1
Oct 2012-2013
n=306
Year 2
Oct 2013-2014
n=255
Total
Oct 2012-2014
n=561
Age, mean (SD) 47 (14.8) 50 (15.1) 48 (14.9)
Gender n, (%) Male 121(39.4) 110 (43.3) 231 (41.2)
Female 181 (60.6) 144 (56.7) 325 (58.8)
Diagnosis n, (%) Type 1 89 (28.9) 60 (23.6) 149 (26.6)
Type 2 218 (71.1) 194 (76.4) 412 (73.4)
Ethnic group n, (%)
Caucasian 76 (24.7) 81 (31.9) 157 (28.0)
African/Caribbean 98 (31.9) 88 (34.6) 186 (33.2)
Other 133 (43.2) 88 (33.5) 218 (38.8)
HbA1cmean (SD)
% (DCCT) 10.7 (1.9) 11.6 (2.1) 11.1 (2.0)
mmol/mol (IFCC) 93 (10) 103 (11) 98 (10)
3DFD characteristicsYear 1
Oct 2012-2013
n=306
Year 2
Oct 2013-2014
n=255
Total
Oct 2012-2014
n=561
Age, mean (SD) 47 (14.8) 50 (15.1) 48 (14.9)
Gender n, (%) Male 121(39.4) 110 (43.3) 231 (41.2)
Female 181 (60.6) 144 (56.7) 325 (58.8)
Diagnosis n, (%) Type 1 89 (28.9) 60 (23.6) 149 (26.6)
Type 2 218 (71.1) 194 (76.4) 412 (73.4)
Ethnic group n, (%)
Caucasian 76 (24.7) 81 (31.9) 157 (28.0)
African/Caribbean 98 (31.9) 88 (34.6) 186 (33.2)
Other 133 (43.2) 88 (33.5) 218 (38.8)
HbA1cmean (SD)
% (DCCT) 10.7 (1.9) 11.6 (2.1) 11.1 (2.0)
mmol/mol (IFCC) 93 (10) 103 (11) 98 (10)
0
5
10
15
20
Glicazide Gliptin Dapagliflozin Lamb/Swk DICT(n=472)
3DFD (n=185)
Impr
ovem
ent i
n Hb
A1c,
mm
ol/m
ol
Agents producing improved glycaemic control
Improvement in HbA1c, mmol/mol
Pre 3DFD Post 3DFD Change score p-value
Mean (SD) DCCT % (n=185) 11.3 (2.1) 10 .0 (2.0) 1.5 (1.6)
Psychiatric morbidity
0
20
40
60
80
100
120
Nil Knowndiagnosis
Newdiagnosis
New relapse
N
Psychiatric Diagnosis
Psychiatric diagnosis: new, known or relapse
Chart1
BPAD
Psychosis
Depression
Anxiety Disorder
Dementia
Eating Disorder
Alcohol dependence
Adjustment Disorder
Personality Disorder
Learning disabililty
Medically unexplained syndromes
Mild psychological
Number of patients with diagnosis
Psychiatric diagnosis
n
Psychiatric diagnoses*
3
13
87
22
5
9
15
29
11
10
8
31
Sheet1
Number of patients with diagnosis
BPAD3
Psychosis13
Depression87
Anxiety Disorder22
Dementia5
Eating Disorder9
Alcohol dependence15
Adjustment Disorder29
Personality Disorder11
Learning disabililty10
Medically unexplained syndromes8
Mild psychological31
243
Social Needs
Social Needs
0
5
10
15
20
25
Support worker assisting patient with type 2 diabetes with her housing situation
Quantitative outcomesPre 3DFD Post 3DFD Change score p-value
Mean HbA1c, mmol/mol (SD)** 102 (22) 84 (22) -18 (17)
Main 3DFD outcomes - economic
Pre 3DFD Post 3DFD Change score p-value
No of admissions to A&E/previous year (n=119) 141 77 -64
Cost-benefit analysis
Costs £94k/borough/year• 0.5WTE Consultant liaison psychiatrist• Community outreach worker• Admin support and infrastructure
Savings £127k/borough/year (-on-year)• Short term: reduction in
unscheduled care• Long term: reduction in developing
diabetes complications
3DFD net saving £33K/100 patients/borough/year recurrent≈ 35% return on investment per year
Patient testimonial
My name is Rochelle, I am a single parent with two children. I had difficulties controlling my diabetes. I became very depressed. 3DFD has managed to help me to overcome my fears of dealing with diabetes. I now use my insulins better.....Rochelle:(T1DM) HbA1c 15.2 to 8.7%
Quality in Care Awards 2011
BMJ Awards 2014Diabetes Team of the Year
Mary McKinnon Lecture DUK 2015
NHS Innovation Challenge Prize 2015
3DFD
Translation of research
Cross sector
integration
Health inequalities
Cost effective
DisseminationOxford Surrey
HillingdonEdinburgh
Parsonage M, Fossey M, Tutty C. Liaison Psychiatry in the Modern NHS. Centre for mental Health, London. 2012, p35.
3DFD
The Future
• Scaling up– Identifying low vs high risk groups– Other long term physical conditions – Across the mental health trust
• Health Foundation Scaling Up Bid 2016 – Shortlisted to final round– Results next week – Watch this space
Regional Innovation
Fund
http://www.guysandstthomas.nhs.uk/Home.aspxhttp://www.guysandstthomas.nhs.uk/Home.aspx
3 Dimensions for Diabetes (3DFD)Rochelle.....Slide Number 3Diabetes is associated with nearly every psychiatric disorderSocial problems3DFD: a blank canvasParallel versus integrated servicesActive ingredients of 3DFD3 Dimensions For Diabetes (3DFD) 1,2,3�Challenges and Opportunities �Slide Number 11Slide Number 12Slide Number 13Slide Number 143DFD outcomes – HbA1c Psychiatric morbidity Social Needs Social NeedsSupport worker assisting patient with type 2 diabetes with her housing situationQuantitative outcomesMain 3DFD outcomes - economicCost-benefit analysisPatient testimonialQuality in Care Awards 2011Slide Number 25The Future Regional Innovation Fund